TB-500
ALSO SOLD AS Thymosin Beta-4 fragment
Last reviewed 2026-10-30
Our read Opinion
FDA lists the fragment among withdrawn nominations. Full-length thymosin beta-4 trials do not validate TB-500; WADA 2026 S2.3 prohibits TB-500.
- Type
- Research-only / unapproved
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- Injection
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to aid recovery and tissue repair
The LKKTETQ fragment is associated with thymosin beta-4 actin-binding biology. Tissue-repair claims often extrapolate from the full-length protein rather than establish fragment efficacy.
No FDA approval. FDA identifies TB-500 as the thymosin beta-4 fragment LKKTETQ and reports no identified human exposure data for that fragment.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
1 news items in last 30 days
Identity matters: the fragment and full-length thymosin beta-4 are not interchangeable evidence packages. Recovery claims lack reliable fragment-specific human support.
WADA
Testing bodies note an increase in adverse findings involving unapproved peptides.
Skin quality, collagen, hair, and faster healing after procedures.
Whole-body repair: injury healing plus gut lining support, skin and hair quality, and lower inflammation.
Faster recovery from tendon, ligament, muscle and joint injuries; less inflammation; quicker return to training.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.